Engineered immune cells take aim at multiple sclerosis and myasthenia gravis
NCT ID NCT07392528
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a new treatment called QT-019C in up to 15 adults with relapsed or refractory neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. The treatment uses donor-derived CAR T-cells that target two proteins (CD19 and BCMA) on immune cells to potentially calm the overactive immune attack on the nervous system. The main goals are to check safety and find the right dose, with some early looks at whether it helps symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Universal allogeneic CAR T-cells targeting CD19 and BCMA
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat neurological autoimmune diseases like multiple sclerosis or myasthenia gravis.
What could go wrong
This is a very early, small trial with only 15 participants, so results may not apply broadly. There are also risks like severe immune reactions or nerve damage from the CAR T-cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Huanhu Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact